Research Article | Open Access
Volume 2021 - 1 | Article ID 189 | http://dx.doi.org/10.51521/IRJCPT.2021.1104
Academic Editor: Darko Medin
KONDA RAVI KIRAN1, S. SWETHA1,
N. KRISHNA REDDY1, SK. AFRIN1 DR. KUDIPUDI HARINADHA
BABA2
1Pharm. D, Narayana Pharmacy
College, Nellore, Andhra Pradesh, India.
2Principal, Narayana Pharmacy
College, Nellore, Andhra Pradesh, India
Corresponding Author: Konda
Ravi Kiran, Pharm. D, Narayana Pharmacy College, Nellore, Andhra
Pradesh, India, Email: harinadha_baba@yahoo.co.in
Citation: Konda Ravi Kiran, S. Swetha, N.
Krishna Reddy, SK. Afrin, Dr. Kudipudi Harinadha Baba (2021) Cost Effectiveness Analysis of Streptokinase and Tenecteplase in
the Treatment of Coronary Thrombosis in a Tertiary Care Teaching Hospital. Int
Res J Clin Stud Pharm Trends, 1(1);1-6.
Copyright: © 2021, Konda Ravi Kiran, S. Swetha,
N. Krishna Reddy, SK. Afrin, Dr. Kudipudi Harinadha Baba. This is an
open-access article distributed under the terms of the Creative Commons
Attribution 4.0 International License, which permits unrestricted use,
distribution and reproduction in any medium, provided the original author and
source are credited.
ABSTRACT:
To Analyse the costs and outcomes of the Streptokinase (STK) and
Tenecteplase (TNP) for the Coronary Thrombotic patients and to provide the
finer Therapeutic outcome. A Prospective Observational Study was
carried out in a Narayana Superspeciality and Tertiary care teaching hospital
(Dept. of Cardiology) and Narayana Pharmacy College for a period of 6 months
among 123 patients. The data was collected by the patient data forms and
specialized questionnaire and the costs and outcome for STK and TNP were
evaluated. Pregnant women were excluded from the study.In this study out of 180
patients 123 patients were willing to provide information. Demographics like
age, gender, marital status, educational status, employment status were
evaluated. Males are more effected compare with females. 50 -60 age people are
more prone to get coronary thrombosis. The cost of the STK is 2270 rs/- and TNP
is 34500 rs/- and the cost difference is 32230 rs/-. The ICER for the STK was
56.75 and TNP was to be 522.7 were evaluated with the use of statistical
formula. This study shows that the STK is more cost effective drug than the TNP.
As compared to the cost of STK with TNP, STK is of less cost and easily
bearable to the patients. So instead of giving other, STK is cost effective as
per Incremental cost effectiveness ratio (ICER).
KEYWORDS:
Cost effective
analysis, Streptokinase, Tenecteplase, Coronary Thrombosis, ICER.
.png)
.jpg)
.gif)
.jpg)
